Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Has Average Price Target of $38.67

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has been given a consensus rating of “Hold” by the five analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $38.67.

A number of research firms recently issued reports on PHAR. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Wall Street Zen raised Pharming Group to a “hold” rating in a research report on Saturday. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd.

Institutional Trading of Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd largest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

Pharming Group Stock Up 6.3%

Pharming Group stock opened at $11.90 on Tuesday. The firm has a market cap of $842.28 million, a PE ratio of 99.17 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. The firm’s 50 day moving average price is $10.69 and its two-hundred day moving average price is $13.92. Pharming Group has a twelve month low of $9.11 and a twelve month high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, research analysts predict that Pharming Group will post 0.32 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.